AnaptysBio reports Q4 2023 net loss of $42.2M, cash $417.9M; pipeline on track

ANAPTYSBIO, INC

Q4 net loss $42.2M ($1.59 per share); full-year net loss $163.6M ($6.08 per share).
Cash & investments $417.9M at Dec 31, 2023 (down from $584.2M year-end 2022); runway through 2026.
R&D spend $33.5M in Q4, up 43% YoY, driven by rosnilimab, ANB032, and ANB033 manufacturing.
ANB032 Phase 2b atopic dermatitis top-line data expected by year-end 2024; rosnilimab RA data mid-2025, UC data H1 2026.
IND filings for ANB033 (anti-CD122) in Q2 2024 and ANB101 (BDCA2) in H2 2024; ANB101 licensed for $7M upfront.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ANAPTYSBIO, INC reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 11, 2024, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and year ended December 31, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-24-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.